SCHEMBL1979735

SCHEMBL1979735

COc1cccc(Oc2ccc(N[C@H](C)C(N)=O)cn2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.42
SYK P43405 2/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.40
PIK3CA P42336 1/20 0.39
SCN9A Q15858 5/20 0.39
FPR2 P25090 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 1/20 0.38
LTA4H P09960 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
MEN1 O00255 2/20 0.38
PABPC1 P11940 1/20 0.38
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979061 0.82 SCN9A (0.41) KEAP1SYKKMT2AALDH1A1POLB
SCHEMBL21980948 0.81 KMT2A (0.52) KEAP1KMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL1979737 0.81 KMT2A (0.52) KEAP1KMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL1979601 0.81 SCN9A (0.46) SYKKMT2AALDH1A1PIK3CASCN9A
SCHEMBL13721111 0.81 SCN9A (0.46) SYKKMT2AALDH1A1PIK3CASCN9A
SCHEMBL1980797 0.80 LTA4H (0.43) SYKKMT2AALDH1A1POLBSCN9A
SCHEMBL13832401 0.78 KMT2A (0.51) KEAP1KMT2AALDH1A1POLBLMNA
SCHEMBL1981054 0.77 FPR2 (0.46) SYKKMT2AALDH1A1SCN9AFPR2
SCHEMBL1980122 0.76 SCN9A (0.45) SYKKMT2ASCN9AFPR2LTA4H
SCHEMBL15303625 0.76 PIK3CA (0.38) SYKLMNAPIK3CASCN9AFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885SYK 3336/4885KMT2A 530/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885SYK 3336/4885KMT2A 530/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885SYK 3336/4885KMT2A 530/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885SYK 3336/4885KMT2A 530/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885SYK 3336/4885KMT2A 530/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885SYK 3336/4885KMT2A 530/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 2956/4885SYK 3709/4885KMT2A 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.